Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03846427 · OUTCOME

Time to Treatment Failure (TTF)

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma · Source last updated 2024-10-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Up to approximately 3 years and 2.5 months

What was measured

TTF is defined as the time from study treatment start to the date of discontinuation of study drug due to any reason.

Analysis population: Efficacy analysis set consisted of all participants with a confirmed diagnosis of MZL who received at least 1 dose of study drug

Groups in this outcome

Zanubrutinib

Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Zanubrutinib66

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Zanubrutinib27.8Not reported14.7NANot estimable due to insufficient number of participants with events and high censoring rate for time-to-event variable
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Not estimable due to insufficient number of participants with events and high censoring rate for time-to-event variable
        group Id
        OG000
        lower Limit
        14.7
        upper Limit
        NA
        value
        27.8
denoms
  1. counts
    1. group Id
      OG000
      value
      66
    units
    Participants
description
TTF is defined as the time from study treatment start to the date of discontinuation of study drug due to any reason.
dispersion Type
95% Confidence Interval
groups
  1. description
    Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent
    id
    OG000
    title
    Zanubrutinib
param Type
MEDIAN
population Description
Efficacy analysis set consisted of all participants with a confirmed diagnosis of MZL who received at least 1 dose of study drug
reporting Status
POSTED
time Frame
Up to approximately 3 years and 2.5 months
title
Time to Treatment Failure (TTF)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice